Clearside Biomedical, Inc. stock is up 44.44% since 30 days ago. The next earnings date is Mar 7, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 50% of the previous 7 November’s closed higher than October. 100% of analysts rate it a buy.
Clearside Biomedical, Inc. focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide suprchoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX and CLS-301, an integrin inhibitor suspension for macular degeneration.